Description
Pediatric Vaccines:
- Combinations
- Hepatitis
- HIB
- MMR
- Pneumococcal
- Poliovirus
- Varicella
- Other Pediatric
Adult Vaccines:
- Cervical Cancer
- Hepatitis
- Influenza
- Pneumococcal
- Travel; DT; Misc.
Kalorama has expanded the global perspective of this report in this edition, including estimates of vaccine sales (pediatric and adult segments) in the following regions:
- U.S.
- Rest of North Amer.
- South America
- Europe
- Japan
- India
- China
- Rest of World
Despite ongoing improvements in pediatric vaccination, it is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. This problem is most significant in low income countries, with the health disparity between rich and poor countries resulting in average life spans of about 77 and 52 years, respectively. In addition to this high death toll, millions more suffer disability and illness because they have not been immunized. Adult immunization is an important, but frequently overlooked, part of patient care. Vaccination programs typically focus on children, yet adults in industrialized countries are more likely to die as a result of vaccine-preventable diseases than are children.
Key issues in the global vaccine market today include product safety, refusal to immunize, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems.The following issues are discussed in this report.
- Vaccine Safety
- Refusal to Immunize
- Obesity
- Post-Licensure Surveillance
- The Future of Vaccine Safety
- Vaccine Shortages
- Preventing Pandemics
- Project Bioshield Act
- National Bio and Agro-Defense Facility
- DNA Vaccination
- Mucosal Delivery
- Intranasal Delivery
- Vaccine Patches
- Vaccine Chips and Microneedles
- Innovations in Vaccine Production
- Nanoparticle Systems
- Cloning
Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission.For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, immunization rates for these diseases continue to be low in the elderly populations. This report includes profiles of the key players in vaccines, including:
- AlphaVax, Inc.
- Bavarian Nordic A/S
- Baxter Healthcare
- Bharat Biotech
- Crucell /Johnson & Johnson
- Emergent biosolutions
- GlaxoSmithKline
- Medimmune
- Merck & Co. Inc
- Novartis
- Sanofi Pasteur
- Pfizer
